ClinicalTrials.gg
CompletedNCT01976312CamelliaUpdated May 30, 2017Results posted

Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)

A Phase 3 interventional study of Sham injection and Ranibizumab 0.5 mg in Central Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 34 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.

Enrollment
9th of 47
252 · median 56
Started
2013
with 6 others
Phase 3
13 of 47
none open now
Registered
31st of 47
by date
Lead sponsor
9 of 47
Novartis Pharmaceuticals

Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 9th largest by enrollment, is one of 7 that started in 2013, is one of 13 in phase 3, and was the 31st registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 47 studies testing ranibizumab in Retinal Vein Occlusion as a file.
02

Study summary

Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO

03

Conditions studied

  • Central Retinal Vein Occlusion

Keywords

  • CRVO, macular edema, vision impairment, retinal vein occlusion, ranibizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with visual impairment secondary to central retinal vein occlusion (CRVO) with a BCVA between 24 and 73 letters in one eye and at least 35 letters in the other eye.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women or women of child bearing potential unless using an effective

    • Stroke or myocard infarction within 3 months prior to study
  • History of within the past 5 years
  • Uncontrolled hypertension
  • Active infection or inflammation in any eye
  • use of for at least 30 days in the last 6 months
  • treatment with anti-angiogenic drugs in any eye within last 3 months
  • Panretinal or focal/drid laser photocoagulation within the last 3 and 4 months respectively
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg

    PRN intravitreal injection

    Drug: Ranibizumab 0.5 mg

  • Sham comparator
    Sham injection

    As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections

    Other: Sham injection

Interventions

  • OtherSham injection

    Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.

  • Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 3 and compared to Baseline.

    Time frame: Baseline, 3 Months

Secondary outcomes

  1. Average Change of Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 12

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline

    Time frame: Baseline, 12 months

  2. Best Corrected Visual Acuity (BCVA) Change From Baseline Over Time

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline

    Time frame: Month 1 to 12 months

  3. Change From Baseline in Central-Sub-Field- Thickness (CSFT) Over Time

    OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center.

    Time frame: Month 1 to month 12

  4. Number of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.

    Time frame: Month 1 to month 12

  5. Number of Participants With Best Corrected Visual Acuity (BCVA)Loss of <15 Letters in the Study Eye Over Time

    Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.

    Time frame: Month 1 to 12 months

  6. The Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 3, 6 and 12 Compared to Baseline

    The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.

    Time frame: Month 3,6 and 12

07

Results

Posted Apr 24, 2017

Participant flow

A total of 253 patients were randomized to this study, 191 patients to the ranibizumab group and 62 patients to the sham group. One patient randomized to the ranibizumab group was excluded from all analyses as informed consent was obtained after first study procedures were performed. Therefore, this patient not included in randomized set.

Participant flow — Overall Study
MilestoneRanibizumab 0.5 mgSham Injection
Started19062
Completed 3 months18660
Discontinued study prior to 3 months42
Completed17353
Not completed179
Withdrew: Pregnancy01
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject72
Withdrew: Adverse event66
Withdrew: Protocol violation20

Outcome measures

PrimaryAverage Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 3 and compared to Baseline.

Time frame:
Baseline, 3 Months
Reported as:
Mean · Letters
Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3
LettersRanibizumab 0.5 mgSham Injection
Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 311.3 ± 10.77-2.7 ± 13.92
Statistical analysis
  • Ranibizumab 0.5 mg vs Sham Injection · Cochran-Mantel-Haenszel · p = <0.001
SecondaryAverage Change of Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 12

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline

Time frame:
Baseline, 12 months
Reported as:
Mean · Letters
Average Change of Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 12
LettersRanibizumab 0.5 mgSham Injection
Average Change of Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 1212.4 ± 11.433.2 ± 14.62
SecondaryBest Corrected Visual Acuity (BCVA) Change From Baseline Over Time

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline

Time frame:
Month 1 to 12 months
Reported as:
Mean · Letters
Best Corrected Visual Acuity (BCVA) Change From Baseline Over Time
LettersRanibizumab 0.5 mgSham Injection
Month 19.6 ± 10.2-0.9 ± 12.17
Month 211.6 ± 12.39-3.4 ± 16.04
Month 312.6 ± 12.01-3.8 ± 17.02
Month 410.7 ± 12.562.8 ± 15.26
Month 511.7 ± 12.623.9 ± 15.26
Month 612.3 ± 13.103.8 ± 17.20
Month 712.9 ± 13.365.0 ± 16.71
Month 812.4 ± 14.016.0 ± 16.01
Month 913.1 ± 15.105.6 ± 16.95
Month 1013.5 ± 14.135.9 ± 16.77
Month 1114.2 ± 13.156.8 ± 16.30
Month 1214.5 ± 14.256.5 ± 17.10
SecondaryChange From Baseline in Central-Sub-Field- Thickness (CSFT) Over Time

OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center.

Time frame:
Month 1 to month 12
Reported as:
Mean · microns
Change From Baseline in Central-Sub-Field- Thickness (CSFT) Over Time
micronsRanibizumab 0.5 mgSham Injection
Month 1-393.7 ± 275.13-13.3 ± 207.55
Month 2-412.6 ± 297.50-7.9 ± 196.65
Month 3-433.3 ± 290.84-84.4 ± 274.98
Month 4-367.8 ± 305.26-364.8 ± 250.48
Month 5-407.0 ± 309.58-369.6 ± 273.92
Month 6-426.6 ± 294.63-372.3 ± 301.24
Month 7-421.5 ± 316.14-392.7 ± 288.74
Month 8-398.9 ± 299.67-405.2 ± 289.49
Month 9-422.1 ± 311.57-393.5 ± 323.50
Month 10-431.7 ± 300.95-395.2 ± 309.67
Month 11-438.1 ± 295.53-417.4 ± 288.08
Month 12-441.7 ± 306.53-416.4 ± 294.08
SecondaryNumber of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.

Time frame:
Month 1 to month 12
Reported as:
Number · Participants
Number of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time
ParticipantsRanibizumab 0.5 mgSham Injection
Month 1 Gain of >=5 letters14117
Month 1 Gain of >=10 letters946
Month 1 Gain of >=15 letters562
Month 1 Gain of >=30 letters30
Month 2 Gain of >=5 letters15018
Month 2 Gain of >=10 letters11911
Month 2 Gain of >=15 letters743
Month 2 Gain of >=30 letters90
Month 3 Gain of >=5 letters15319
Month 3 Gain of >=10 letters11711
Month 3 Gain of >=15 letters764
Month 3 Gain of >=30 letters120
Month 4 Gain of >=5 letters13831
Month 4 Gain of >=10 letters10721
Month 4 Gain of >=15 letters6811
Month 4 Gain of >=30 letters142
Month 5 Gain of >=5 letters14334
Month 5 Gain of >=10 letters11623
Month 5 Gain of >=15 letters8013
Month 5 Gain of >=30 letters131
Month 6 Gain of >=5 letters14739
Month 6 Gain of >=10 letters12128
Month 6 Gain of >=15 letters8712
Month 6 Gain of >=30 letters1413
Month 7 Gain of >=5 letters15237
Month 7 Gain of >=10 letters12129
Month 7 Gain of >=15 letters9114
Month 7 Gain of >=30 letters143
Month 8 Gain of >=5 letters14339
Month 8 Gain of >=10 letters12728
Month 8 Gain of >=15 letters9519
Month 8 Gain of >=30 letters163
Month 9 Gain of >=5 letters14740
Month 9 Gain of >=10 letters12626
Month 9 Gain of >=15 letters9417
Month 9 Gain of >=30 letters173
Month 10 Gain of >=5 letters15239
Month 10 Gain of >=10 letters12829
Month 10 Gain of >=15 letters9516
Month 10 Gain of >=30 letters184
Month 11 Gain of >=5 letters15340
Month 11 Gain of >=10 letters13429
Month 11 Gain of >=15 letters10119
Month 11 Gain of >=30 letters184
Month 12 Gain of >=5 letters15139
Month 12 Gain of >=10 letters13130
Month 12 Gain of >=15 letters9921
Month 12 Gain of >=30 letters243
SecondaryNumber of Participants With Best Corrected Visual Acuity (BCVA)Loss of <15 Letters in the Study Eye Over Time

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.

Time frame:
Month 1 to 12 months
Reported as:
Number · Participants
Number of Participants With Best Corrected Visual Acuity (BCVA)Loss of <15 Letters in the Study Eye Over Time
ParticipantsRanibizumab 0.5 mgSham Injection
Month 1, Loss of < 15 letters18557
Month 2, Loss of < 15 letters18253
Month 3, Loss of < 15 letters18251
Month 4, Loss of < 15 letters17955
Month 5, Loss of < 15 letters18256
Month 6, Loss of < 15 letters18053
Month 7, Loss of < 15 letters18155
Month 8, Loss of < 15 letters17755
Month 9, Loss of < 15 letters17756
Month 10, Loss of < 15 letters18056
Month 11, Loss of < 15 letters18356
Month 12, Loss of < 15 letters18255
SecondaryThe Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 3, 6 and 12 Compared to Baseline

The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.

Time frame:
Month 3,6 and 12
Reported as:
Mean · Scores on a scale
The Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 3, 6 and 12 Compared to Baseline
Scores on a scaleRanibizumab 0.5 mgSham Injection
Month 34.4 ± 12.540.1 ± 13.78
Month 66.7 ± 15.022.9 ± 13.33
Month 128.2 ± 13.703.2 ± 15.34

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg—11/190 (5.8%)96/190 (50.5%)
Sham With Ranibizumab 0.5 mg—5/56 (8.9%)32/56 (57.1%)
Sham Without Ranibizumab 0.5 mg—1/5 (20%)3/5 (60%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventRanibizumab 0.5 mgSham With Ranibizumab 0.5 mgSham Without Ranibizumab 0.5 mg
Macular fibrosisEye disorders0/1900/561/5
Acute myocardial infarctionCardiac disorders0/1901/560/5
Left ventricular dysfunctionCardiac disorders0/1901/560/5
Angle closure glaucomaEye disorders2/1901/560/5
Wrist fractureInjury, poisoning and procedural complications0/1901/560/5
Diabetes mellitusMetabolism and nutrition disorders0/1901/560/5
SchwannomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1901/560/5
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders0/1901/560/5
KeratitisEye disorders1/1900/560/5
Gastric ulcerGastrointestinal disorders1/1900/560/5
Most frequent other events
Showing 10 of 67
Most frequent other events
EventRanibizumab 0.5 mgSham With Ranibizumab 0.5 mgSham Without Ranibizumab 0.5 mg
AsthenopiaEye disorders2/1900/561/5
Dry eyeEye disorders7/1901/561/5
Eye painEye disorders4/1902/561/5
GlaucomaEye disorders2/1900/561/5
Iris neovascularisationEye disorders0/1902/561/5
Visual acuity reducedEye disorders9/1903/561/5
Vitreous detachmentEye disorders1/1900/561/5
DacryocystitisInfections and infestations0/1900/561/5
ParaesthesiaNervous system disorders0/1900/561/5
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/1902/561/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ranibizumab 0.5 mgSham InjectionTotal
Mean54.1 ± 12.6454.1 ± 13.2954.1 ± 12.77
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mgSham InjectionTotal
Female8829117
Male10233135
08

Study locations

34 sites
  • Novartis Investigative Site
    Beijing, Beijing 100191, China
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Chongqing, Chongqing 400042, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510060, China
  • Novartis Investigative Site
    Shantou, Guangdong 515041, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150001, China
  • Novartis Investigative Site
    Wuhan, Hubei 430070, China
  • Novartis Investigative Site
    Changsha, Hunan 410011, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210006, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Nantong, Jiangsu 226000, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Qingdao, Shandong 266011, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300070, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325027, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100176, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Chongqing, 400038, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Shanghai, 200092, China
  • Novartis Investigative Site
    Hongkong, Hong Kong
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380 016, India
  • Novartis Investigative Site
    Bhubaneswar, Orissa 751 024, India
  • Novartis Investigative Site
    Bandung, Jawa Barat 40117, Indonesia
  • Novartis Investigative Site
    Jakarta, 10430, Indonesia
  • Novartis Investigative Site
    Manila, Metro Manila 1000, Philippines
  • Novartis Investigative Site
    San Juan City, 1500, Philippines
  • Novartis Investigative Site
    Lin-Kou, 33305, Taiwan
  • Novartis Investigative Site
    Taipei, Taiwan
  • Novartis Investigative Site
    Hanoi, 10000, Vietnam
  • Novartis Investigative Site
    Ho Chi Minh City, 70000, Vietnam
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Mar 2016, 28 months.

Results were first posted in Apr 2017, 1 year 1 month after primary completion.

Of 18 phase 3 interventional studies under Retinal Vein Occlusion, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2013
First posted
Nov 5, 2013
StartActual
Nov 12, 2013
Primary completionActual
Mar 14, 2016
CompletionActual
Mar 14, 2016
Results first posted
Apr 24, 2017
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01976312
Responsible party
Sponsor
First posted
Nov 5, 2013
Start date
Nov 12, 2013
Primary completion
Mar 14, 2016
Completion
Mar 14, 2016
Results posted
Apr 24, 2017
Last update
May 30, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion